Christopher Arington has been promoted to vice chairman and chief executive officer of authorized generic drug maker Prasco Laboratories.


Prasco Laboratories, Christopher Arington, E. Thomas Arington, David Vucurevich, vice chairman, chief executive officer, CEO, chairman, chief operating officer, COO, authorized generic, David Furniss, chief financial officer, Chris Gilmore, pharmaceutical industry




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

CEO succession, new COO at Prasco

December 6th, 2011

CINCINNATI – Christopher Arington has been promoted to vice chairman and chief executive officer of authorized generic drug maker Prasco Laboratories.

Previously president and chief operating officer, he takes the CEO reins from his father, Prasco chairman and founder E. Thomas Arington.

Also on Tuesday, Prasco promoted David Vucurevich to president and COO. A former pharmaceutical purchasing executive at Rite Aid Corp., Vucurevich joined Prasco as senior vice president of corporate development in the fall of 2009.

"It is an honor to accept the position as Prasco CEO and to join Mr. David Vucurevich in leading Prasco forward," Chris Arington said in a statement. "I am extremely pleased with Prasco's existing leadership team and we look forward to expanding Prasco's role in the pharmaceutical industry."

In addition, the company promoted David Furniss to chief financial officer and Chris Gilmore to vice president of strategic business ventures.

"I am extremely pleased to announce these management changes," E. Thomas Arington commented. "As one of the founders of Prasco, Chris has played a critical role in the development and evolution of the company from day-to-day operations to the larger strategic picture.

"Mr. Vucurevich brings extensive experience in the pharmaceutical industry, as well as a 'get it done' management style and a commitment to excellence, which is so appropriate for Prasco at this point in time," the chairman added. "As CFO, Mr. David Furniss brings financial acumen and over 20 years of pharmaceutical industry experience. Mr. Furniss, along with Mr. Chris Gilmore, a former Prasco authorized generics business executive, will play key roles in developing and implementing new business opportunities, including acquisitions."

Advertisement